The Novel Way to Treat OA in Dogs

There are many challenges that come with treating osteoarthritis (OA) in dogs, from concerns about the safety of long-term solutions to early diagnosis. Galliprant™ is an NSAID you can trust for safe and effective treatment of OA in your canine patients, no matter what stage of their OA journey they are at. Galliprant has been firmly established as an excellent first-line option in the OA treatment space, already improving the quality of life for hundreds of thousands of dogs across the world. After all, an NSAID with an impressive safety profile¹ means less stress for all.

Addressing long-term concerns

The unfortunate reality of OA is that there is no cure, which means long-term treatment is the best course of action to make patients more comfortable. Some dog owners and vets are reluctant to prescribe NSAIDs long-term for fear of damaging side effects on their patients², but Galliprant can be administered safely for life if necessary.

“While osteoarthritis is often associated with old age, this is often not the case in dogs. Canine OA affects many young dogs and these dogs benefit greatly from adequate analgesia that is administered appropriately. Galliprant™ is very effective at treating the pain and inflammation associated with canine osteoarthritis, and it has become my NSAID of choice for the long-term treatment of canine OA. It is important to note that a multimodal approach is required to achieve the best outcome. Using Galliprant together with nutraceuticals and a tailored dietary and exercise regimen is key in achieving a successful outcome.” – Dr. Simon T. Kudnig BVSc, MVS, MS, FACVSc, Dip.ACVS, Specialist in Small Animal Surgery and ACVS Founding Fellow of Surgical Oncology

A targeted mode of action means an impressive safety profile

Galliprant's mode of action directly targets canine OA pain and inflammation while allowing the production of prostaglandins involved in GIT and renal homeostasis³. The benefits of this targeted mode of action are highlighted by the results of a target animal safety study¹. In this study, Galliprant was administered up to ten times the maximum therapeutic dose daily for nine months. Even at these high daily doses, Galliprant was well tolerated by study participants. All dogs completed the study in a clinically normal fashion, with no evidence of gastrointestinal ulceration, and no kidney or liver problems.

Proven results on real patients

We can say what we like about Galliprant, but the results speak for themselves. Efficacy has been proven via a comprehensive clinical study⁴ published in the Journal of Veterinary Internal Medicine. The study draws firm and reassuring conclusions about Galliprant, stating that the medicine is an effective treatment for the alleviation of pain and inflammation in dogs with OA, and represents a modality of treatment that is well tolerated.

Your trusted choiuce for OA relief in dogs

If you’ve been searching for a safe and effective NSAID to treat both early and long-term cases of OA, Galliprant is the name you can trust. It’s a tried-and-true treatment backed by vets, science and studies, so you can prescribe it with peace of mind.

^{Read product leaflet for full instructions. The following mild and generally transient adverse reactions have been observed in dogs treated with grapiprant: vomiting, diarrhoea, inappetance and lethargy. For long-term treatment, appropriate monitoring is recommended. The safety of Galliprant has not been established in dogs less than 3.6 kg or less than nine months of age.}

References

1. Rausch-Derra LC, et al. Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs. AJVR 2015; 76:853-859.
2. Belshaw Z et al. The attitudes of owners and veterinary professionals in the United Kingdom to the risk of adverse events associated with using non-steroidal anti-inflammatory drugs (NSAIDs) to treat dogs with osteoarthritis. Prev Vet Med. 2016; 131: 121-126.
3. Kirkby Shaw K, Rausch-Derra LC, Rhodes L. Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2016; 2:3-9.
4. Rausch-Derra LC, et al. A Prospective, Randomized, Masked, Placebo-Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in Dogs with Osteoarthritis. JVIM 2016; 30:756-763.

^{For further information contact: 1800 995 709 from anywhere in Australia Monday to Friday or email productsupportau@elancoah.com. Galliprant and Elanco diagonal bar logo are trademarks of Elanco or its affiliates. ©2022 Elanco or its affiliates. PM-AU-22-0402.}